Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent

Sanofi's new and acquired medicines generated €1.3 billion in Q2 sales, up 48.3% at constant exchange rates, led by Altuviiio, Ayvakit and Sarclisa. The company forecasts pharma launches will generate roughly €10 billion in annual sales by 2030, diversifying a business where Dupixent accounted for about 42% of first-half 2026 revenue and is projected to reach about €25 billion. Consensus EPS estimates rose to $5.07 for 2026 from $4.96 and to $5.29 for 2027 from $5.18 over 60 days, though the stock remains down 15.5% year to date.

Analysis

The investable issue is not the launch-growth headline but whether Sanofi can convert acquired and newly launched assets into durable, high-margin franchises before Dupixent concentration becomes a valuation constraint. The current multiple discount implies the market assigns limited credit to the 2030 launch target, likely reflecting integration risk around Blueprint, launch spend, and uncertainty over persistence/adherence in specialty indications. Sequential prescription and net-price data for Ayvakit, Altuviiio and Sarclisa should matter more than aggregate launch revenue; sustained growth with stable SG&A leverage could support a rerating toward 9-10x forward EPS over 6-18 months.

REGN is a nuanced read-through rather than a clean beneficiary: Sanofi diversification reduces its dependence on the shared Dupixent economics, but does not impair REGN's contractual profit participation. A more material competitive concern is that Sanofi's capital allocation toward its internal pipeline and acquired oncology portfolio may reduce the strategic premium investors assign to future large-scale immunology collaboration expansion. AZN has modest indirect upside through Beyfortus geographic expansion, though its economics and supply availability—not demand commentary—will determine earnings relevance.

Near-term catalysts are November's FDA decision on venglustat and quarterly launch-product growth/margin disclosures over the next 1-3 months. The key falsifiers are a U.S. regulatory setback for another pipeline asset, weaker-than-expected launch trajectories after initial stocking, or operating-expense growth that absorbs incremental gross profit. Contrarian view: the low multiple may be justified if the market is correctly discounting a portfolio of individually modest assets rather than a cohesive set of blockbusters; the headline target alone is not sufficient for multiple expansion.

Key Decisions for Investors

• Initiate a 6-12 month long SNY position only on evidence of two consecutive quarters of launch-product growth above management's implied trajectory and stable/improving Pharma operating margin; target a rerating from the current depressed earnings multiple toward 9-10x, with thesis invalidated by a material cut to launch guidance or margin deleveraging.
• Use a long SNY / short ABBV pair over 6-12 months for investors seeking to isolate relative multiple normalization: SNY has under-credited launch optionality, while ABBV retains greater single-franchise and biosimilar-transition sensitivity. Size modestly; exit if SNY's launch sales decelerate materially or ABBV's new-immunology portfolio outperforms expectations.
• Treat the November venglustat decision as an event-risk watch rather than a pre-decision options trade until implied volatility and commercial probability are available. A positive decision without a meaningful estimate revision would be a signal that regulatory success is already discounted, not an automatic reason to add.
• Maintain REGN exposure independently of the SNY thesis; monitor Dupixent volume, pricing and profit-share disclosures. Reduce any SNY-to-REGN sympathy positioning if Dupixent growth decelerates, since shared economics remain the dominant earnings linkage.